Navigation

IND Application Submission To FDA For Phase 1 Trial Of Genetically Modified Autologous Cell Therapy For HIV Announced by American Gene Technologies

By AGT | Oct 18, 2019
Filed Under:

ROCKVILLE, Md., Oct. 18, 2019 /PRNewswire/ — American Gene Technologies (AGT) announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for AGT’s lead HIV program, AGT103-T, which is potentially a single-dose, lentiviral vector-based gene therapy developed for the purpose of eliminating HIV from people infected with the disease. “Our aim is to… [Read More]

American Gene Technologies to Present at 2019 Cell & Gene Meeting on the Mesa

By AGT | Oct 2, 2019
Filed Under:

ROCKVILLE, Md., Oct. 01, 2019 (GLOBE NEWSWIRE) — American Gene Technologies announced today that its Chief Science Officer C. David Pauza, Ph.D. will present at the annual Cell & Gene Meeting on the Mesa to be held October 2-4 in Carlsbad, California. Organized by the Alliance for Regenerative Medicine, the… [Read More]

HIV Cure Program of American Gene Technologies Adds University of Maryland School of Medicine’s Institute of Human Virology as New Study Site to Support the Development of a Cell and Gene Therapy for HIV

By AGT | Jul 2, 2019
Filed Under:

ROCKVILLE, Md. — American Gene Technologies (AGT), a leading gene and cell therapy company based in Rockville, MD, selected the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) as a new clinical site for its non-IND study, AGT-CS168, to collect clinical specimens from HIV… [Read More]

HIV Cure Program Patent Granted To American Gene Technologies

By AGT | May 21, 2019
Filed Under:

ROCKVILLE, Md., May 21, 2019 (GLOBE NEWSWIRE) — American Gene Technologies, a leading gene and cell therapy company based in Rockville, Md., was granted a second patent for its unique molecule, methods, and cell process for its HIV program. This patent further protects AGT’s lentiviral vector and proprietary process for generating autologous… [Read More]

AGT Launches Oncology Science Advisory Group to Accelerate Research For A Cancer Cure

By AGT | Mar 25, 2019
Filed Under:

ROCKVILLE, MD, UNITED STATES, March 25, 2019 /EINPresswire.com/ — American Gene Technologies (AGT), a leading gene and cell therapy biotech company based in Rockville, Md., has established an advisory group for the advancement of immunotherapies that activate gamma-delta (γδ) T cells to attack a variety of tumors including liver, prostate,… [Read More]

AGT Granted Fifth Patent Protecting Its Immunotherapy Cancer Cure Asset

By AGT | Mar 21, 2019
Filed Under:

ROCKVILLE, MD, UNITED STATES, March 21, 2019 /EINPresswire.com/ — American Gene Technologies (AGT) recently was awarded a fifth immuno-oncology patent (“Methods and Composition for the Activation of Gamma Delta T cells” US10137144) to protect its lead asset in immunotherapy for cancer. This patent further validates the advances AGT has made towards the treatment… [Read More]

Subscribe to Our Newsletter

Subscribe to our newsletter to keep up to date with all the latest news about AGT!

Mailchimp sidebar

Follow AGT on Social Media

Send this to a friend